文献速递类风湿关节炎

CDK4/6抑制通过增强JUN的泛素依赖性降解对滑膜成纤维细胞产生软骨保护作用

Chondroprotective effects of CDK4/6 inhibition via enhanced ubiquitin-dependent degradation of JUN in synovial fibroblasts.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该研究探讨CDK4/6抑制剂对类风湿关节炎滑膜成纤维细胞的软骨保护机制。在胶原诱导性关节炎模型中,CDK4/6抑制减轻软骨破坏和MMP-3产生;在RASFs中,CDK4/6抑制通过损害JUN稳定性减弱AP-1转录活性,从而抑制MMP-1和MMP-3产生。作者认为CDK4/6药理抑制在RA患者中可能有益。

要点

  • CDK4/6抑制在CIA模型中减轻软骨破坏和MMP-3产生。
  • 在RASFs中CDK4/6抑制损害AP-1组分与DNA结合,抑制MMP-1和MMP-3产生。
  • CDK4/6通过抑制泛素化保护JUN免受蛋白酶体依赖性降解。

核心结论

  • CDK4/6抑制的软骨保护机制是通过损害JUN稳定性减弱AP-1转录活性实现的。
  • 作者认为,由于CDK4/6药理抑制在癌症治疗中已确立为可耐受,其软骨保护和抗炎作用可能使RA患者受益。

研究设计与样本

  • 研究通过CDKI处理或腺病毒基因转导增强CDK4/6活性,在胶原诱导性关节炎模型(CIA)中评估软骨保护作用。
  • 采用定量PCR、ELISA和Western blotting评估基因和蛋白表达,用电泳迁移率变动分析评估核提取物与DNA结合,用RNA-Seq鉴定CDKI影响的基因集。

主要发现

  • CDKI在CIA中减轻软骨破坏和MMP-3产生。
  • 在RASFs中,CDKI损害AP-1组分与DNA结合,抑制含AP-1结合序列启动子的MMP-1和MMP-3产生。
  • CDK4/6通过抑制泛素化保护JUN免受蛋白酶体依赖性降解。
  • RNA-Seq分析鉴定出CDKI敏感的炎症基因,这些基因与RA相关基因通路、细胞因子-细胞因子受体相互作用和IL-17信号传导相关,且AP-1基序在这些基因中富集。

临床怎么用

  • 作者认为,由于CDK4/6药理抑制在癌症治疗中已确立为可耐受,其软骨保护和抗炎作用可能使RA患者受益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Targeting synovial fibroblasts (SF) using a cyclin-dependent kinase (CDK) 4/6 inhibitor (CDKI) could be a potent therapy for RA via inhibition of proliferation and MMP-3 production. This study was designed to elucidate the mechanism of chondroprotective effects on SFs by CDK 4/6 inhibition. METHODS: CDK4/6 activity was inhibited using CDKI treatment or enhanced by adenoviral gene transduction. Chondroprotective effects were evaluated using a collagen-induced arthritis model (CIA). Gene and protein expression were evaluated with quantitative PCR, ELISA and Western blotting. The binding of nuclear extracts to DNA was assessed with an electrophoresis mobility shift assay. RNA-Seq was performed to identify gene sets affected by CDKI treatment. RESULTS: CDKI attenuated cartilage destruction and MMP-3 production in CIA. In RASFs, CDKI impaired the binding of AP-1 components to DNA and inhibited the production of MMP-1 and MMP-3, which contain the AP-1 binding sequence in their promoter. CDK4/6 protected JUN from proteasome-dependent degradation by inhibiting ubiquitination. The RNA-Seq analysis identified CDKI-sensitive inflammatory genes, which were associated with the pathway of RA-associated genes, cytokine-cytokine receptor interaction and IL-17 signalling. Notably, the AP-1 motif was enriched in these genes. CONCLUSION: The mechanism of chondroprotective effects by CDK4/6 inhibition was achieved by the attenuation of AP-1 transcriptional activity via the impaired stability of JUN. Because the pharmacologic inhibition of CDK4/6 has been established as tolerable in cancer treatment, it could also be beneficial in patients with RA due to its chondroprotective and anti-inflammatory effects.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hosoya T, Saito T, Baba H, et al. Chondroprotective effects of CDK4/6 inhibition via enhanced ubiquitin-dependent degradation of JUN in synovial fibroblasts. Rheumatology (Oxford). 2022. PMID: 34849618. doi:10.1093/rheumatology/keab874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。